These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24576794)

  • 21. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
    Vandever MA; Kuehl TJ; Sulak PJ; Witt I; Coffee A; Wincek TJ; Reape KZ
    Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.
    Halbreich U; Freeman EW; Rapkin AJ; Cohen LS; Grubb GS; Bergeron R; Smith L; Mirkin S; Constantine GD
    Contraception; 2012 Jan; 85(1):19-27. PubMed ID: 22067793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial.
    Hadji P; Neulen J; Schaudig K; Schwenkhagen A; Grimmbacher S; Wiegratz I
    Gynecol Endocrinol; 2020 Jun; 36(6):513-520. PubMed ID: 32064971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unscheduled bleeding with continuous oral contraceptive pills: a comparison of progestin dose.
    Kaneshiro B; Edelman A; Carlson NE; Nichols M; Jensen J
    Contraception; 2012 Jul; 86(1):22-7. PubMed ID: 22176792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and biochemical investigations of a variable-dose combined type oral contraceptive.
    Briggs MH; Briggs M
    Curr Med Res Opin; 1977; 5(3):213-6. PubMed ID: 162656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
    Nelson AL; Kaunitz AM; Kroll R; Simon JA; Poindexter AN; Castaño PM; Ackerman RT; Flood L; Chiodo JA; Garner EI;
    Contraception; 2021 Mar; 103(3):137-143. PubMed ID: 33259782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).
    Archer DF; Maheux R; DelConte A; O'Brien FB
    Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 2):39-44. PubMed ID: 10561674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
    Anderson FD; Gibbons W; Portman D
    Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
    Archer DF; Kovalevsky G; Ballagh SA; Grubb GS
    Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M
    Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
    Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
    Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
    Kaunitz AM; Portman D; Westhoff CL; Archer DF; Mishell DR; Foegh M
    Contraception; 2015 Mar; 91(3):204-10. PubMed ID: 25582984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations.
    Rosenberg MJ; Meyers A; Roy V
    Contraception; 1999 Dec; 60(6):321-9. PubMed ID: 10715366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
    Kaunitz AM; Portman D; Westhoff CL; Archer DF; Mishell DR; Rubin A; Foegh M
    Obstet Gynecol; 2014 Feb; 123(2 Pt 1):295-303. PubMed ID: 24402597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.